Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: belzutifan | 1.00 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 6 Parkinson's papers of 823 | 0.74 |
| pathways Reactome | 8 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 6980
Sealed predictions
- EPAS1 in dopamine neurons, braak+0.28 (p 0.466) → -0.26 (p 0.500)receipt 6987
Swarm cases
receipt 6987: EPAS1 in dopamine neurons, braak
- power
- full sample +0.02 (p 0.928, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.976, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.10 (p 0.690, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.15, sign flips 7; without severely affected donors +0.02 (p 0.928, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EPAS1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts